Cargando…

Development of diabetes mellitus associated with quetiapine: A case series

We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanasawa, Hideki, Sako, Akahito, Mitsutsuka, Tomohiko, Nonogaki, Kaori, Kondo, Tadayuki, Mishima, Shuichi, Uju, Yoriyasu, Ito, Toshihiko, Enomoto, Tetsuro, Hayakawa, Tatsuro, Yanai, Hidekatsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279094/
https://www.ncbi.nlm.nih.gov/pubmed/28099349
http://dx.doi.org/10.1097/MD.0000000000005900
_version_ 1782502714632044544
author Nanasawa, Hideki
Sako, Akahito
Mitsutsuka, Tomohiko
Nonogaki, Kaori
Kondo, Tadayuki
Mishima, Shuichi
Uju, Yoriyasu
Ito, Toshihiko
Enomoto, Tetsuro
Hayakawa, Tatsuro
Yanai, Hidekatsu
author_facet Nanasawa, Hideki
Sako, Akahito
Mitsutsuka, Tomohiko
Nonogaki, Kaori
Kondo, Tadayuki
Mishima, Shuichi
Uju, Yoriyasu
Ito, Toshihiko
Enomoto, Tetsuro
Hayakawa, Tatsuro
Yanai, Hidekatsu
author_sort Nanasawa, Hideki
collection PubMed
description We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after initiation of quetiapine. We excluded patients who developed diabetes more than 1 year after discontinuation of quetiapine. We identified new-onset diabetes by hemoglobin A1c or prescriptions of antidiabetic drugs. Among 1688 patients who received quetiapine, hemoglobin A1c had been measured in 595 (35.2%) patients at least once during the observation period, and 33 (2.0%) patients had received hypoglycemic drugs. Eighteen (1.1%) patients were considered to have developed new-onset diabetes associated with quetiapine after a median of 1.6 years following initiation of quetiapine. Median (interquartile range) age was 54.5 (29.8) years, 8 patients were male, and median (interquartile range) duration of mental illness was 15.3 (13.8) years. Median hemoglobin A1c and body mass index (BMI) were 7.1 (1.4) % and 28.4 (7.0) kg/m(2), respectively. Seventeen patients had dyslipidemia when diabetes was discovered. All of these discontinued quetiapine within 3 months after the diagnosis of diabetes, and the diabetes in 4 patients had ameliorated without hypoglycemic drugs. Of 13 patients who had received either oral hypoglycemic drugs or insulin, 2 patients achieved well-controlled hemoglobin A1c without hypoglycemic drugs, and 10 patients had hemoglobin A1c 5.0% to 7.7% with the continued use of hypoglycemic drugs. We demonstrated that almost all patients who developed quetiapine-associated diabetes had dyslipidemia and increased BMI. There was no life-threatening hyperglycemia and diabetes was ameliorated just by discontinuation of quetiapine in several patients. The monitoring of metabolic parameters during antipsychotic treatment is important to diagnose and treat diabetes earlier.
format Online
Article
Text
id pubmed-5279094
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52790942017-02-08 Development of diabetes mellitus associated with quetiapine: A case series Nanasawa, Hideki Sako, Akahito Mitsutsuka, Tomohiko Nonogaki, Kaori Kondo, Tadayuki Mishima, Shuichi Uju, Yoriyasu Ito, Toshihiko Enomoto, Tetsuro Hayakawa, Tatsuro Yanai, Hidekatsu Medicine (Baltimore) 5000 We aimed to describe the characteristics and clinical course of patients who developed diabetes associated with the use of quetiapine. This study included patients who received quetiapine for over a month between April 2008 and November 2013, and were diagnosed as having new-onset diabetes after initiation of quetiapine. We excluded patients who developed diabetes more than 1 year after discontinuation of quetiapine. We identified new-onset diabetes by hemoglobin A1c or prescriptions of antidiabetic drugs. Among 1688 patients who received quetiapine, hemoglobin A1c had been measured in 595 (35.2%) patients at least once during the observation period, and 33 (2.0%) patients had received hypoglycemic drugs. Eighteen (1.1%) patients were considered to have developed new-onset diabetes associated with quetiapine after a median of 1.6 years following initiation of quetiapine. Median (interquartile range) age was 54.5 (29.8) years, 8 patients were male, and median (interquartile range) duration of mental illness was 15.3 (13.8) years. Median hemoglobin A1c and body mass index (BMI) were 7.1 (1.4) % and 28.4 (7.0) kg/m(2), respectively. Seventeen patients had dyslipidemia when diabetes was discovered. All of these discontinued quetiapine within 3 months after the diagnosis of diabetes, and the diabetes in 4 patients had ameliorated without hypoglycemic drugs. Of 13 patients who had received either oral hypoglycemic drugs or insulin, 2 patients achieved well-controlled hemoglobin A1c without hypoglycemic drugs, and 10 patients had hemoglobin A1c 5.0% to 7.7% with the continued use of hypoglycemic drugs. We demonstrated that almost all patients who developed quetiapine-associated diabetes had dyslipidemia and increased BMI. There was no life-threatening hyperglycemia and diabetes was ameliorated just by discontinuation of quetiapine in several patients. The monitoring of metabolic parameters during antipsychotic treatment is important to diagnose and treat diabetes earlier. Wolters Kluwer Health 2017-01-20 /pmc/articles/PMC5279094/ /pubmed/28099349 http://dx.doi.org/10.1097/MD.0000000000005900 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5000
Nanasawa, Hideki
Sako, Akahito
Mitsutsuka, Tomohiko
Nonogaki, Kaori
Kondo, Tadayuki
Mishima, Shuichi
Uju, Yoriyasu
Ito, Toshihiko
Enomoto, Tetsuro
Hayakawa, Tatsuro
Yanai, Hidekatsu
Development of diabetes mellitus associated with quetiapine: A case series
title Development of diabetes mellitus associated with quetiapine: A case series
title_full Development of diabetes mellitus associated with quetiapine: A case series
title_fullStr Development of diabetes mellitus associated with quetiapine: A case series
title_full_unstemmed Development of diabetes mellitus associated with quetiapine: A case series
title_short Development of diabetes mellitus associated with quetiapine: A case series
title_sort development of diabetes mellitus associated with quetiapine: a case series
topic 5000
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279094/
https://www.ncbi.nlm.nih.gov/pubmed/28099349
http://dx.doi.org/10.1097/MD.0000000000005900
work_keys_str_mv AT nanasawahideki developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT sakoakahito developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT mitsutsukatomohiko developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT nonogakikaori developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT kondotadayuki developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT mishimashuichi developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT ujuyoriyasu developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT itotoshihiko developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT enomototetsuro developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT hayakawatatsuro developmentofdiabetesmellitusassociatedwithquetiapineacaseseries
AT yanaihidekatsu developmentofdiabetesmellitusassociatedwithquetiapineacaseseries